Its name is a mouthful, but it’s the vaccine on everyone’s lips: The ChAdOx1 nCoV-19, currently being developed by Oxford University scientists, has in recent days shot ahead to become the most promising potential vaccine against the novel coronavirus.
On Thursday, the British drug maker AstraZeneca said it would help Oxford develop, produce and distribute the vaccine.
“Our hope is that, by joining forces, we can accelerate the globalisation of a vaccine to combat the virus and protect people from the deadliest pandemic in a generation,” AstraZeneca Chief Executive Pascal Soriot said.
The partnership hopes to produce 100 million doses by the end of the year and prioritize supply in the UK, Soriot told the Financial Times.
The first good news came last week from a laboratory in the US state of Montana, where six rhesus macaques, who received a dose of the British vaccine a month ago, did not contract Covid-19 after being exposed to it. Other monkeys who had not been vaccinated caught the virus and fell ill.
“The rhesus macaque is pretty much the closest thing we have to humans,” Vincent Munster, the scientist who conducted the experiment, told The New York Times.
Morgane Bomsel, a molecular biologist working on Covid-19 at the Cochin Institute in Paris, agrees. “It’s true that it’s better than if the tests had been carried out on mice,” she told FRANCE 24.
Bomsel considers the results encouraging, but warns against celebrating too soon, if only because details of the experiment conducted in Montana have not yet been published. “We don’t know yet, for example, what dose of the virus the macaques were exposed to, or how they were contaminated,” she said.
First tests on humans in Europe
Work on the ChAdOx1 nCov-19 vaccine is moving ahead quickly in Britain as well. On April 24, the Oxford vaccine was the first in Europe to enter the human trial stage, with 1,110 healthy volunteers recruited for the tests.
“The goal is to ensure that the vaccine is not toxic for the human body,” Bomsel said. In other words, before checking whether the ChAdOx1 nCov-19 protects from Covid-19, the researchers first need to guarantee that it is not dangerous.
The next step usually is to “take blood samples from the subjects to check for the presence of antibodies and the effectiveness of the vaccine against the coronavirus”, Bomsel explained.
If the trial produces positive results, millions of doses of ChAdOx1 nCov-19 could be available as early as September, Oxford researchers told the New York Times, months ahead of other known efforts.
“Usually, in fact, it takes about 18 months,” a member of the crisis cell of the French Society for Virology (SVF), a network of over 1,000 virologists from different laboratories, told FRANCE 24.
Modular vaccine
The Oxford scientists might be able to work at record speed “because in a sense, this vaccine isn’t new”, said the SVF virologist, who asked to remain anonymous because she did not want to involve her employer in the debate.
The researchers used a “technological platform with which they already have quite a lot of experience”, she said.
The core of the vaccine – ChAdOx1 – is an adenovirus: that is, it belongs to a family of viruses that have a mild effect on humans, and it is present in chimpanzees.
“It exists in humans as well, but researchers preferred to take it from monkeys to be certain that the human body has not already developed antibodies to protect against it,” she explained.
It is then combined with parts of another virus to make a vaccine. Researchers at Oxford have already used ChAdOx1 in the past to test vaccines against Ebola, Chikungunya, Rift Valley fever and, above all, the Middle East Respiratory Syndrome (MERS) virus, a coronavirus related to Covid-19 that was first reported in 2012. British scientists had very encouraging results in the latter case, especially with tests on rhesus macaques.
For the current coronavirus, they simply “added the surface protein of Covid-19 to ChAdOx1”, said Bomsel. That is the part of the virus that allows it to attach to the host cells and infect them. The purpose of the vaccine would therefore be to allow the human body to develop defenses against this mechanism of attaching to a human cell.
Since the technology is already in place and they have already tested humans for other vaccines using ChAdOx1, the Oxford scientists were quickly able to adapt it to the current pandemic and develop the clinical trial protocols.
Ring vaccination strategy
But even if the results of the clinical trial currently under way end up being promising, it will still be too early to celebrate.
The following step, Phase III of the vaccine’s development, will be to administer it to volunteers who will then be released back into their regular environments where they could be exposed naturally to the virus. The complete process of ensuring that these subjects are effectively immune to the disease can take up to three years.
So how can British scientists commit to providing doses of ChAdOx1 by September if the trials succeed? By following a specific procedure for cases where there is not enough time to complete testing: ring vaccination.
“The idea is to administer the vaccine to members of the first circle of contacts of people who fall ill with the virus, and then to observe whether the virus contaminates the second circle. That way, it’s possible both to vaccinate and to evaluate,” explained the French virologist.
This was done during the 2018 Ebola epidemic in the Democratic Republic of the Congo and could be replicated to fight against Covid-19.
While the experts interviewed by FRANCE 24 recognised that the work of the Oxford team was very promising, they said other possible vaccines – like those being developed by the American pharmaceutical companies Inovio and Moderna – might also be in advanced stages of research by the autumn.
Despite the encouraging news, there is no guarantee that the vaccines will work. But even if the efforts at Oxford University are unsuccessful, Bomsel said, “we will at least have learned a lot about how the body’s immune system fights this virus”.
The FSV virologist was even more optimistic: “Even if the vaccine won't successfully immunise the body against Covid-19, we can still hope that it will reduce the severity of the virus,” she said.
That alone would be preferable to watching, more or less helplessly, as the number of coronavirus victims grows every day.
WATCH:
This article has been translated from the original French.
AFP/File / WANG ZHAO
POOL/AFP/File / Ulrich Perrey 
AFP / Anthony WALLACE 
AFP / THOMAS COEX 
AFP / Dibyangshu SARKAR 
AFP / PEDRO PARDO 
AFP / TONY KARUMBA 
AFP / DANIEL LEAL-OLIVAS 
AFP / ANDY BUCHANAN 
AFP / Tolga AKMEN 
AFP / Abhisek SAHA